Spain’s Almirall has consolidated its existing relationship with BioFocus, the UK-based drug discovery specialist and Galapagos affiliate, by announcing a three-year research alliance aimed at delivering “drug development candidates directed to a key respiratory target of interest to Almirall”.
The collaboration could be worth as much as €7.5 million to BioFocus, which will apply its integrated drug discovery capabilities to supplement Almirall’s respiratory expertise. The Spanish company’s core therapeutic areas include asthma and chronic obstructive pulmonary disease (COPD).
Parexel yesterday announced that they have extended their alliance network for early-phase research by partnering with University Hospitals Bristol National Health Service Foundation Trust (UH Bristol), which is one of the UK’s biggest specialist training and research hospital trusts.
GlaxoSmithKline (GSK) has unveiled the anti-doping research laboratory which will be used to help catch drug cheaters at the London 2012 Olympic and Paralympic Games.
Bayer has provided more information about their recently-halted late-stage trial of their colorectal cancer drug, regorafenib, which shows that the drug improved overall survival by 29%, meeting its primary endpoint.
The mobile healthcare smartphone application market increased seven-fold to reach $718 million in 2011, but is set to rise much more in the future, according to the Mobile Health Market Report 2011-2016.
A new joint partnership between BioCity Nottingham and Scotland’s Roslin BioCentre, known as BioCity Scotland, announced yesterday has given Scotland’s life sciences sector a major boost, taking away some of the disappointment of MSD’s decision to close down their pharmaceutical research facility at Newhouse, Scotland.
Clinical Professionals are proud to announce that we have secured two finalist places for PharmaTimes’ Clinical Recruiter of the Year competition.
Although Eli Lilly expects to meet or exceed their current earnings per share guidance for 2011 of $3.84-$3.89, the company has announced that profits for 2012 will be $3.10-$3.20 per share, well below analysts’ estimations.
Arena Pharmaceuticals and partner Eisai are optimistic that regulators will approve their obesity drug, lorcaserin, after responding to a rejection issued by the US Food and Drug Administration in October 2010.
